Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CLVS

Clovis Oncology (CLVS) Stock Price, News & Analysis

Clovis Oncology logo

About Clovis Oncology Stock (NASDAQ:CLVS)

Key Stats

Today's Range
N/A
50-Day Range
$0.08
$1.09
52-Week Range
N/A
Volume
1.16 million shs
Average Volume
8.88 million shs
Market Capitalization
$11.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CLVS Stock News Headlines

Clovis Chamber names new Retail Rockstar
I’m sounding the alarm
Two Nobel Prize winners are warning of The Final Displacement — a powerful shift that could spark one of the largest wealth transfers in modern history. According to Goldman Sachs, thousands of Americans are already being financially upended each day while others quietly grow richer. Which side you’re on may depend on what you do next.tc pixel
Cancer Horoscope
See More Headlines

CLVS Stock Analysis - Frequently Asked Questions

Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to the consensus estimate of $38.73 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clovis Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY), NIO (NIO) and Micron Technology (MU).

Company Calendar

Last Earnings
11/03/2021
Today
10/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CLVS
CIK
1466301
Employees
N/A
Year Founded
2009

Profitability

EPS (Trailing Twelve Months)
($1.83)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$264.52 million
Net Margins
-189.37%
Pretax Margin
-189.68%
Return on Equity
N/A
Return on Assets
-57.78%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.14
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$148.76 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.15) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
144,955,000
Free Float
138,577,000
Market Cap
$11.60 million
Optionable
Optionable
Beta
0.24

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:CLVS) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners